RenovaCare products are under development and not approved for sale in the United States.

Results may vary from person to person.

RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

RenovaCare Provides Clinical and Corporate Update

Scottsdale, AZ – March 09, 2022 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced that following the review of its research and corporate activities, the Company is taking steps to streamline its clinical, research and development, and administrative operations in order to reduce costs.

RenovaCare Responds to SEC Complaint

Roseland, NJ – June 1st, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced that it intends to vigorously defend itself and its stockholders against allegations made by the U.S. Securities and Exchange Commission (“SEC”) in a civil complaint filed on May 28, 2021 regarding legacy events (the “Complaint”) from over 3 years ago.

RenovaCare to Present at H.C. Wainwright Global Life Science Conference March 9-10, 2021

Roseland, NJ – February 25th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at the 2021 H.C. Wainwright Global Life Sciences Conference, scheduled for March 9 – 10.